New combo therapy for CLL tested in Real-World settings

NCT ID NCT07602088

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see how many respond and what factors influence doctors' decisions. The goal is to understand the real-world effectiveness of this fixed-duration therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibrutinib and venetoclax
What this could lead to: If successful, this study could confirm that a fixed-duration combination of ibrutinib and venetoclax is effective and practical for routine treatment of CLL, potentially offering a time-limited therapy option.
What could go wrong: This is an observational study with only 60 participants, so results may not apply to all patients. The combination can cause side effects like heart rhythm problems, bleeding, or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL

Contacts and locations

Locations

Spitalul Universitar de Urgenta Bucuresti
RECRUITING

Bucharest, 050098, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.